Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by Teacher Retirement System of Texas

Teacher Retirement System of Texas lowered its position in Travere Therapeutics, Inc. (NASDAQ:TVTXFree Report) by 9.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 17,001 shares of the company’s stock after selling 1,803 shares during the quarter. Teacher Retirement System of Texas’ holdings in Travere Therapeutics were worth $153,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also made changes to their positions in the stock. Jump Financial LLC raised its stake in Travere Therapeutics by 232.3% during the 3rd quarter. Jump Financial LLC now owns 188,925 shares of the company’s stock valued at $1,689,000 after purchasing an additional 132,067 shares during the period. Barclays PLC boosted its holdings in Travere Therapeutics by 14.3% during the third quarter. Barclays PLC now owns 288,654 shares of the company’s stock valued at $2,579,000 after acquiring an additional 36,071 shares during the period. Swiss National Bank boosted its holdings in Travere Therapeutics by 7.0% during the third quarter. Swiss National Bank now owns 147,600 shares of the company’s stock valued at $1,320,000 after acquiring an additional 9,700 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Travere Therapeutics by 4.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 565,919 shares of the company’s stock valued at $5,059,000 after buying an additional 25,566 shares during the period. Finally, State of New Jersey Common Pension Fund D bought a new stake in shares of Travere Therapeutics in the third quarter valued at about $1,693,000.

Travere Therapeutics Stock Performance

NASDAQ TVTX opened at $7.02 on Friday. The company’s 50 day moving average is $6.53 and its 200-day moving average is $7.57. The firm has a market cap of $534.43 million, a P/E ratio of -3.34 and a beta of 0.69. Travere Therapeutics, Inc. has a 12-month low of $5.12 and a 12-month high of $19.54. The company has a quick ratio of 2.75, a current ratio of 2.78 and a debt-to-equity ratio of 5.10.

Travere Therapeutics (NASDAQ:TVTXGet Free Report) last released its quarterly earnings results on Monday, May 6th. The company reported ($1.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.78). Travere Therapeutics had a negative return on equity of 238.06% and a negative net margin of 87.94%. The company had revenue of $41.40 million during the quarter, compared to analysts’ expectations of $43.46 million. During the same period in the prior year, the firm earned ($1.27) EPS. Travere Therapeutics’s quarterly revenue was up 34.0% on a year-over-year basis. Sell-side analysts predict that Travere Therapeutics, Inc. will post -3.66 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on TVTX. Canaccord Genuity Group raised their price target on shares of Travere Therapeutics from $15.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday, May 7th. HC Wainwright reissued a “buy” rating and issued a $19.00 price objective on shares of Travere Therapeutics in a report on Tuesday, May 7th. Guggenheim reaffirmed a “neutral” rating on shares of Travere Therapeutics in a report on Wednesday, March 27th. Wedbush reiterated an “outperform” rating and set a $13.00 price objective on shares of Travere Therapeutics in a research report on Wednesday, April 17th. Finally, Wells Fargo & Company upped their price target on shares of Travere Therapeutics from $8.00 to $9.00 and gave the company an “equal weight” rating in a research report on Friday, February 16th. Five equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $15.58.

Read Our Latest Research Report on TVTX

About Travere Therapeutics

(Free Report)

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.

Featured Articles

Institutional Ownership by Quarter for Travere Therapeutics (NASDAQ:TVTX)

Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.